Every 10-Q that Cardio Diagnostics Holdings Inc (CDIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CDIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDIO filings page.
Cardio Diagnostics Holdings develops AI‑driven blood tests for cardiovascular disease. For the quarter ended June 30, 2026, it generated revenue of $5,360 and incurred a net loss of $1,501,468, or $0.51 per share, on operating expenses of $1,503,507.
For the first six months of 2026, revenue was $8,040 with a net loss of $3,289,626. Cash was $5,586,697 at June 30, 2026, and stockholders’ equity totaled $7,426,283, against total liabilities of $499,780.
The company continues to fund operations primarily through equity, including $3,693,470 of net proceeds from at‑the‑market share sales in 2026. With 2,959,469 shares outstanding, management notes ongoing operating losses, modest revenue to date, and dependence on future capital raises and broader test adoption.
Cardio Diagnostics Holdings, Inc. reported a first-quarter 2026 net loss of $1,788,158 on very early-stage revenue of $2,680, reflecting continued investment ahead of broad commercialization. Operating expenses were $1,787,517, driven mainly by general and administrative costs, sales and marketing, and research and development.
Cash increased to $7,077,021 as of March 31, 2026, helped by $3,693,470 in net proceeds from at-the-market common stock sales, leaving stockholders’ equity at $8,903,399. The company continues to expand adoption of its AI-driven cardiovascular tests, build evidence, and rely on equity financing while acknowledging its disclosure controls were not effective.
Cardio Diagnostics (CDIO) filed its Q3 2025 10-Q, showing minimal sales and ongoing investment in operations. Revenue was $2,855 for the quarter and $11,270 year-to-date. Operating expenses were $1,714,452 in Q3 and $5,032,126 year-to-date. The company reported a net loss of $1,714,536 for Q3 and $5,032,799 for the first nine months.
Cash stood at $6,355,218 as of September 30, 2025, with net cash used in operating activities of $4,364,984 year-to-date. The share count increased as the company raised capital: 1,766,607 shares were outstanding at quarter-end and 1,826,051 as of November 12, 2025. The company executed a 1-for-30 reverse stock split effective May 12, 2025 to maintain Nasdaq compliance. Through its at-the-market program, the company has sold shares for net proceeds of $15,061,270 as of November 12, 2025, including a post-quarter sale of 59,444 shares for $269,813.